Loading...
Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group
Despite intensified salvage treatments, children with relapsed/refractory acute myeloid leukemia (AML) have poor survival. We evaluated gemtuzumab ozogamicin (CD33-targeted drug) used on a compassionate basis in patients diagnosed from 1995 until 2014 within Acute Myeloid Leukemia Berlin-Frankfurt-M...
Na minha lista:
| Udgivet i: | Haematologica |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Ferrata Storti Foundation
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6312035/ https://ncbi.nlm.nih.gov/pubmed/30093401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.191841 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|